Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:MRUS NASDAQ:NUVL NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.19-1.4%$12.80$6.38▼$16.66$1.50B1.571.41 million shs1.42 million shsMRUSMerus$68.09-2.1%$64.40$33.19▼$70.65$5.26B1.19574,619 shs763,483 shsNUVLNuvalent$79.37-1.4%$78.71$55.53▼$113.51$5.80B1.29391,654 shs403,823 shsTGTXTG Therapeutics$31.75-1.3%$32.30$21.16▼$46.48$5.10B1.881.98 million shs1.91 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%-2.28%+12.49%+62.11%+12.41%MRUSMerus0.00%+3.13%+3.46%+30.54%+38.77%NUVLNuvalent0.00%-0.52%+5.83%+5.44%-7.98%TGTXTG Therapeutics0.00%-0.16%+14.53%-9.74%+35.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.19-1.4%$12.80$6.38▼$16.66$1.50B1.571.41 million shs1.42 million shsMRUSMerus$68.09-2.1%$64.40$33.19▼$70.65$5.26B1.19574,619 shs763,483 shsNUVLNuvalent$79.37-1.4%$78.71$55.53▼$113.51$5.80B1.29391,654 shs403,823 shsTGTXTG Therapeutics$31.75-1.3%$32.30$21.16▼$46.48$5.10B1.881.98 million shs1.91 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%-2.28%+12.49%+62.11%+12.41%MRUSMerus0.00%+3.13%+3.46%+30.54%+38.77%NUVLNuvalent0.00%-0.52%+5.83%+5.44%-7.98%TGTXTG Therapeutics0.00%-0.16%+14.53%-9.74%+35.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.11Buy$20.8637.31% UpsideMRUSMerus 3.08Buy$88.7530.34% UpsideNUVLNuvalent 3.08Buy$120.9152.34% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2545.67% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, NUVL, TGTX, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$115.009/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/4/2025NUVLNuvalentGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$122.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.009/2/2025NUVLNuvalentRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$105.008/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$112.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M8.72N/AN/A$0.77 per share19.73MRUSMerus$36.13M142.53N/AN/A$9.46 per share7.20NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ATGTXTG Therapeutics$329M15.31$0.12 per share268.08$1.43 per share22.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.030.00253.17N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)MRUSMerus-$215.33M-$5.500.00N/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)NUVLNuvalent-$260.76M-$4.900.00N/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3786.9231.75N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest AVDL, NUVL, TGTX, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.792.38MRUSMerusN/A8.398.39NUVLNuvalentN/A13.5713.57TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%MRUSMerus96.14%NUVLNuvalent97.26%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%MRUSMerus3.70%NUVLNuvalent10.20%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableAVDL, NUVL, TGTX, and MRUS HeadlinesRecent News About These CompaniesGreat Lakes Advisors LLC Takes $401,000 Position in TG Therapeutics, Inc. $TGTXSeptember 15 at 3:50 AM | marketbeat.comIntech Investment Management LLC Grows Stock Holdings in TG Therapeutics, Inc. $TGTXSeptember 15 at 3:19 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Director Sagar Lonial Sells 20,852 SharesSeptember 14 at 5:32 PM | marketbeat.comUnited Services Automobile Association Purchases Shares of 8,531 TG Therapeutics, Inc. $TGTXSeptember 14 at 4:02 AM | marketbeat.comInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13 at 6:38 AM | insidertrades.comWoodline Partners LP Takes $21.02 Million Position in TG Therapeutics, Inc. $TGTXSeptember 13 at 4:36 AM | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingSeptember 10, 2025 | globenewswire.comTG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple SclerosisSeptember 8, 2025 | quiverquant.comQTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced EnrollmentSeptember 8, 2025 | globenewswire.comCinctive Capital Management LP Purchases Shares of 14,145 TG Therapeutics, Inc. $TGTXSeptember 8, 2025 | marketbeat.comWhy TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback ProgramSeptember 7, 2025 | finance.yahoo.comBanque Transatlantique SA Invests $610,000 in TG Therapeutics, Inc. $TGTXSeptember 6, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Still a Buy?September 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.com683 Capital Management LLC Reduces Holdings in TG Therapeutics, Inc. $TGTXSeptember 4, 2025 | marketbeat.comTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comWhy Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?September 3, 2025 | zacks.comTG Therapeutics completes share repurchase program, authorize new $100M programSeptember 3, 2025 | msn.comTG Therapeutics Board Authorizes New $100M Share Repurchase ProgramSeptember 3, 2025 | msn.comTG Therapeutics Completes $100 Million Share Repurchase Program and Authorizes New $100 Million Repurchase InitiativeSeptember 3, 2025 | quiverquant.comQTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million ProgramSeptember 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, NUVL, TGTX, and MRUS Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$15.19 -0.21 (-1.36%) Closing price 04:00 PM EasternExtended Trading$15.18 0.00 (-0.03%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Merus NASDAQ:MRUS$68.09 -1.49 (-2.14%) Closing price 04:00 PM EasternExtended Trading$69.15 +1.06 (+1.56%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Nuvalent NASDAQ:NUVL$79.37 -1.10 (-1.37%) Closing price 04:00 PM EasternExtended Trading$79.41 +0.04 (+0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$31.75 -0.41 (-1.27%) Closing price 04:00 PM EasternExtended Trading$31.75 0.00 (0.00%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
